Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trialsGary Lichtenstein, William J. Sandborn, A. Olson et al.|Alimentary Pharmacology & Therapeutics|2009Cited by 195
Infliximab Reduces Colectomy in Patients with Moderate-to-Severe Ulcerative Colitis: Analysis from ACT 1 and ACT 2William J. Sandborn, J F Colombel, P. Rutgeerts et al.|The American Journal of Gastroenterology|2007Cited by 2
Long-term maintenance of remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohnʼs disease exacerbation: 3-year results from the PRECiSE 4 studyWilliam J. Sandborn, Gary Lichtenstein, Stefan Schreiber et al.|Inflammatory Bowel Diseases|2009Cited by 1
Sustained remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohn's disease exacerbation who were naïve to anti-TNF treatmentWilliam J. Sandborn, Gary Lichtenstein, J F Colombel et al.|Inflammatory Bowel Diseases|2011Cited by 0